DoH Policies screened during the period: 1 January 2022 -31 March 2022
Date published: 04 May 2022
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.
NICE Technology Appraisal TA752 - Belimumab for treating active autoantibody-positive systemic lupus erythematosus (review of TA397) (PDF 514KB)